Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR3
- Development stage
- Preclinical
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
CR3 is a recombinant multi-epitope protein vaccine candidate developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, for the treatment and prevention of HIV/AIDS. The vaccine construct is engineered to include highly conserved regions of the HIV-1 Gag, Pol, and Env proteins. By targeting these stable segments of the viral genome, CR3 aims to elicit a broad and effective immune response that can overcome the high genetic variability and mutation rate characteristic of HIV-1. Currently in the preclinical stage of development, CR3 is being evaluated for its ability to induce both cellular (T-cell) and humoral (B-cell) immunity, and it serves as a key component in CIGB's broader HIV vaccine strategy, which includes multi-antigen and multi-platform approaches like TERAVAC-HIV.
- Other names
- CIGB-CR3CIGB-CR-3CIGB-CR 3HIV-1 CR3 vaccineHIV1 CR3 vaccineHIV 1 CR3 vaccineCenter for Genetic Engineering and Biotechnology HIV vaccine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNef (HIV-1 Nef)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on CR3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CR3.